Last Updated: October 3, 2025
Analyzing Management
Leadership within public companies serves as a significant variable for hedge funds and asset managers during both initial due diligence and continuous risk assessment. ManagementTrack offers a consistent methodology that eliminates distractions, highlighting explicit strengths and weaknesses, identifying warning signs and positive indicators, and establishing a straightforward connection between CEO actions and financial performance.
CEO Greenstreet’s launch skill may not overcome execution & profitability risks.
Analysis of Alnylam Pharmaceuticals CEO Yvonne Greenstreet
Despite strong commercial launch experience, Yvonne Greenstreet’s mixed record on international execution and profitability may temper expectations for Alnylam’s global expansion and long-term financial goals.
Management evaluated Yvonne Greenstreet’s track record and skillset against the following key factors for ALNY:
- Mitigating GTN pressure to protect AMVUTTRA’s net revenue.
- Executing AMVUTTRA’s key international launches.
- Delivering sustained profitability via operating leverage.
- Sustaining AMVUTTRA’s strong launch momentum in ATTR-CM.
Yvonne Greenstreet’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
As Greenstreet executes the critical international launches for AMVUTTRA, will she apply a standardized commercial playbook that risks repeating the European failure of Xeljanz, or will she demonstrate the strategic discipline to adapt her approach to unique regional regulatory and reimbursement hurdles?
Question #2
Now that Alnylam must deliver sustained profitability, will Greenstreet pivot from her successful ‘builder’ playbook of aggressive investment in commercial infrastructure to an ‘operator’ mindset focused on cost discipline, even if it means sacrificing future growth opportunities?
Why Do Investors Use ManagementTrack?
How does ManagementTrack evaluate an executive such as Yvonne Greenstreet at ALNY?
ManagementTrack builds a detailed profile of an executive’s track record, core competencies, and potential blind spots through its proprietary career analysis and interviews with former colleagues. This profile is then benchmarked against a company’s most critical challenges; for ALNY, these factors include mitigating gross-to-net pressure on AMVUTTRA’s revenue, executing the drug’s key international launches, delivering sustained profitability through operating leverage, and maintaining AMVUTTRA’s strong launch momentum.
What additional proprietary signals does ManagementTrack analyze to link executive teams to future performance?
ManagementTrack utilizes a suite of proprietary models to generate further predictive insights. Its models are designed to flag executive evasion during earnings call Q&A, identifying when such behavior is abnormal. The system also scrutinizes all insider transactions to pinpoint outliers that may predict future stock outperformance or underperformance. These signals contribute to the ManagementTrack Rating, a predictive 1-10 score assigned to every executive, providing investors with a clear, directional view on how management will likely impact company results.
What is the scope of ManagementTrack’s coverage?
ManagementTrack provides real-time analytical coverage on the C-suite of every publicly traded company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Yvonne Greenstreet
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Alnylam Pharmaceuticals, Inc. 10Q
- Alnylam Pharmaceuticals, Inc. 10K
- Alnylam Pharmaceuticals, Inc. Earnings Calls
- Alnylam Pharmaceuticals, Inc. Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
